Leveraging JAK Inhibitors in Ulcerative Colitis: Strategies for the IBD Management Team

Leveraging JAK Inhibitors in Ulcerative Colitis: Strategies for the IBD Management Team

On-Demand Webcast
OVERVIEW

IBD is a chronic gastrointestinal disorder that includes both Crohn’s disease (CD) and UC. IBD affects an estimated 1 to 1.3 million people aged ≥18 years in the United States, with UC affecting  an estimated 907,000 Americans. UC is a disease that commonly afflicts young adults and is characterized by relapsing and remitting mucosal inflammation in the rectum and colon. The advent of biologic medications has greatly improved the ability of clinicians to control this disease, but a number of clinical gaps remain: not all patients respond to biologics, and many who do respond develop immunogenicity; the effects of biologic medications on individual patients are difficult to predict; and the onset of action of these medications is often measured over the course of months. JAK inhibitors, which are small-molecule drugs, may offer an additional treatment option for many patients with UC.

FACULTY

Hans H. Herfarth, MD, PhD
Professor of Medicine
Division of Gastroenterology and Hepatology
University of North Carolina at Chapel Hill

Chapel Hill, North Carolina

PROVIDER STATEMENT

Provided by North American Center for Continuing Medical Education, LLC (NACCME), an HMP Company.

For questions regarding this educational activity, please call 609-371-1137 or email info@naccme.com.

INTENDED LEARNERS

This activity is designed and certified for the entire IBD healthcare team and includes education for gastroenterologists, pediatric gastroenterologists, surgeons, physicians, PhDs, researchers, pharmacists, nurse practitioners, physician assistants, gastroenterology nurses, and residents/fellows/students.

LEARNING OBJECTIVES

After participating in this activity, learners should be better able to:

  • Describe differentiating characteristics between small-molecule drugs and biologic drugs
  • Outline available JAK inhibitor efficacy and safety data
  • Utilize best practice guidance when considering JAK inhibitor treatment for patients with UC
CLAIMING CREDIT

To be eligible for credit, participants must complete the online activity and the evaluation. Upon completing the activity, there will be instructions on how to complete the evaluation and print a certificate or other documentation of credit.

Release Date: October 30, 2020
Expiration Date: October 30, 2021 
Estimated Time to Complete: 0.5 hours

There is no fee associated with this activity.

EDUCATION GRANT

NACCME would like to thank the following company who has supported this program through an educational grant: Pfizer.

CONTINUING EDUCATION

 

In support of improving patient care, NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIANS

NACCME designates this internet enduring activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSING

This continuing nursing education activity awards 0.5 contact hours.

Provider approved by the California Board of Registered Nursing, Provider #13255 for 0.5 contact hours. 

PHARMACY

This internet enduring, knowledge-based activity (Universal Activity Number: JA0006201-0000-20-189-H01-P) has been approved for a maximum of 0.5 contact hours (.05 CEUs).

The certificate is not the official record of your participation in the activity. The official record of credit will be the information in CPE Monitor system. The deadline to claim credit is December 30, 2021 (60 DAYS AFTER ACTIVITY). Following ACPE Policy, NACCME will not be able to report your claimed credit to CPE Monitor after this 60-day period. Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended.

PHYSICIAN ASSISTANTS

NACCME has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 credit(s). PAs should only claim credit commensurate with the extent of their participation.

USE OF PROPRIETARY NAMES

This continuing medical education activity may include device or medicine brand names for participant clarity purposes only, due to the presence of different branded versions of the same product. No product promotion or recommendation should be inferred.

UNAPPROVED AND/OR INVESTIGATIONAL USES OF DRUGS AND DEVICES

This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the European Medicines Agency (EMA) of the European Union or the Food and Drug Administration (FDA) of the United States. Participants are strongly encouraged to consult approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed during this activity are the opinions of the respective authors, presenters or moderators and do not necessarily reflect the opinions of NACCME.

DISCLAIMERS

The material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.

Neither NACCME nor any of its subsidiaries or affiliates is affiliated with, or formally endorsed by a medical society.

The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME or HMP. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.

DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS

NACCME, LLC is an independent provider(s) of continuing medical education. NACCME, LLC has no proprietary or financial interest in medical or healthcare products over which the FDA (USA) or EMA (EU) has regulatory authority.

NACCME, LLC assures that all educational materials are reviewed to ensure for the absence of commercial bias, fair balance, scientific objectivity, and levels of evidence. The educational activity will not be influenced by commercial organizations and will not conflict with any other scheduled educational activities.

According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

 

Planning Committee

In addition to the faculty listed below, NACCME planners and staff include Christopher Bolwell, Samantha Conforti, Lara Gray, Damon Harper, Mary Johnson, Randy Robbin, Greaton Sellers, and Leslie Sharp. 

Christopher Bolwell is a shareholder of GlaxoSmithKline. GlaxoSmithKline is not supporting this activity, nor does any content relate to their products or services.

No other planner has disclosed a relevant financial relationship with any commercial interest.

Faculty

The faculty has reported the following disclosures:

Hans H. Herfarth, MD, PhD: Consultant-Alivio, Boehringer Ingelheim, Finch Therapeutics, Gilead, Janssen, Pfizer; Grant/Research Support-Allakos, Artizan, Pfizer

ADA STATEMENT

North American Center for Continuing Medical Education (NACCME) complies with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please call 609-371-1137.

PRIVACY POLICY

NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint providers. NACCME and our joint providers will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate accrediting agency. NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2020 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education.

GRIEVANCE POLICY

Any participant wanting to file a grievance with respect to any aspect of a continuing education activity accredited by NACCME, LLC may contact Samantha Conforti, Manager, Accreditation and Compliance, by phone at 609-371-1137, by email at sconforti@naccme.com or in writing at 104 Windsor Center Drive, East Windsor, NJ 08520. The Manager, Accreditation and Compliance will review the grievance and respond within 30 days of receiving the complaint. If the participant is unsatisfied with the response, an appeal to the Senior Manager/Director or the Executive Vice President, Chris Bolwell, Accreditation and Compliance, can be requested for a second level of review. Mr. Bolwell can be contacted via phone at 678-242-0801, by email at c.bolwell@imedex.com or in writing at 11675 Rainwater Drive, Suite 600 Alpharetta, GA 30009.